Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman, M.D. will present and host investor meetings at two January 2026 conferences in San Francisco: Sachs Associates 9th Annual Neuroscience Innovation Forum on Jan 11, 2026 (presentation 11:55 a.m. PT; panel 1:15 p.m. PT) and Biotech Showcase on Jan 13, 2026 (presentation 11:00 a.m. PT). A replay will be posted on the company website and investor meetings can be requested via sebastian.gomez@astrpartners.com.

Company highlights: marketed products TONMYA for fibromyalgia, Zembrace SymTouch and Tosymra for acute migraine, plus a CNS, immunology, rare disease and infectious disease pipeline including TNX-102 SL, TNX-1500, TNX-2900, TNX-801, TNX-4800 and TNX-4200 (DTRA contract up to $34M).

Key Figures

Conference date January 11, 2026 Sachs Associates 9th Annual Neuroscience Innovation Forum company presentation

Second session time 1:15 p.m. PT Innovation in Neuropsychiatric Drug Development panel on January 11, 2026

Biotech Showcase date January 13, 2026 Biotech Showcase 2026 company presentation in San Francisco

TNX-1500 stage Phase 2-ready Fc-modified monoclonal antibody targeting CD40-ligand for allograft rejection and autoimmunity

TNX-4800 stage Phase 2-ready Long-acting monoclonal antibody for seasonal prevention of Lyme disease

TNX-4200 contract value $34 million Up to five-year DTRA contract for broad-spectrum antiviral development

TNX-4200 contract term five years DTRA funding period for antiviral program targeting CD45

FDA status TONMYA FDA-approved First-in-class non-opioid analgesic for fibromyalgia, first new drug in >15 years

Market Reality Check

$15.63 Last Close

Volume Volume 873,900 vs 20-day average 512,588 (relative volume 1.7x) shows elevated trading ahead of conference appearances. high

Technical Shares at 15.22 are trading below the 200-day MA of 27.03 and about 78% under the 52-week high of 69.97.

Peers on Argus

Peers show mixed moves: NMRA -11.14%, CADL -3.28%, OMER -5.93%, VNDA -5.18%, while ANNX gained 10.13%. TNXP’s -8.04% move appears more stock-specific than part of a uniform sector trend.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 29	Equity offering	Negative	+0.1%	Registered direct offering raising <b>$20M</b> for commercialization and pipeline.
Dec 29	Program update	Positive	+0.1%	Program updates on Phase 2/3‑ready TNX‑4800 for Lyme disease prevention.
Dec 16	Licensing deal	Positive	-1.4%	Exclusive worldwide license of TNX‑4900 for chronic neuropathic pain.
Dec 09	Management change	Neutral	-1.5%	Appointment of new General Counsel to oversee legal and compliance.
Nov 24	Clinical milestone	Positive	-11.3%	FDA IND clearance for Phase 2 HORIZON study in major depressive disorder.

Pattern Detected

Recent news (clinical, licensing, financing) often produced modest or negative next-day moves, including a double‑digit decline on positive MDD trial clearance.

Recent Company History

Over the last few months, Tonix reported several key milestones, including FDA IND clearance for a Phase 2 MDD study of TNX-102 SL on Nov 24, 2025, licensing neuropathic pain candidate TNX-4900 on Dec 16, 2025, and program updates for Lyme disease antibody TNX-4800 on Dec 29, 2025. It also completed a $20.0M registered direct offering on Dec 29, 2025. Despite these developments, price reactions ranged from slightly positive to notably negative, suggesting a cautious market stance heading into today’s conference-focused announcement.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-09-04

The company has an active S-3/A shelf registration dated 2025-09-04, with at least one recorded usage via a 424B5 filing on 2025-11-21, indicating the ability to access equity markets under this program.

Market Pulse Summary

This announcement outlines Tonix’s participation in January 2026 investor conferences, giving management a platform to highlight FDA‑approved TONMYA and a broad CNS, immunology, rare disease, and infectious disease pipeline. Recent history includes key steps such as IND clearance for major depressive disorder and Lyme disease program updates, alongside equity financing. Investors may watch for new clinical timelines, commercialization metrics, and any capital plans discussed around these events to contextualize the stock’s position relative to its 52-week range.

Key Terms

monoclonal antibody medical

"a Phase 2- ready Fc-modified humanized monoclonal antibody targeting CD40-ligand"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

cd40-ligand medical

"monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed"

CD40 ligand is a protein displayed on certain immune cells and platelets that acts like a switch, turning on other immune cells and helping the body make antibodies and inflame tissues. Investors care because drugs that block or mimic this molecule can alter immune responses—potentially treating autoimmune disease, transplant rejection, or cancer—but such therapies can also affect blood clotting and inflammation, creating both opportunity and safety risk.

investigational new drugs regulatory

"product development candidates are investigational new drugs or biologics"

Investigational new drugs are medicines that are being tested in people but have not yet been approved for general use by health authorities. They matter to investors because clinical trial results and regulatory decisions determine whether these prototypes become sellable products—success can unlock large future revenues, while failures or delays can sharply reduce a company’s expected value, much like a prototype that may or may not make it to market.

biologics medical

"product development candidates are investigational new drugs or biologics"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

prader-willi syndrome medical

"TNX-2900, intranasal oxytocin ... in development for Prader-Willi syndrome"

A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.

mpox medical

"TNX-801, a vaccine in development for mpox and smallpox"

Mpox is an infectious viral disease that causes fever, rash and swollen lymph nodes and spreads through close contact; think of it like a less common cousin of seasonal illnesses that can lead to local outbreaks. It matters to investors because outbreaks can change demand for medical supplies, affect healthcare and insurance costs, disrupt travel and workforce availability, and trigger regulatory or public health responses that influence company revenues and risk profiles.

smallpox medical

"TNX-801, a vaccine in development for mpox and smallpox"

Smallpox is a highly contagious and often severe viral disease caused by the variola virus, characterized by fever and a distinctive blistering rash; it historically caused widespread illness and death before global eradication through vaccination. For investors, smallpox matters because any evidence of its presence, research, or policy changes triggers regulatory action, public-health spending and shifts in demand for vaccines, diagnostics and security measures, similar to how a wildfire forces rapid, resource-heavy responses.

AI-generated analysis. Not financial advice.

BERKELEY HEIGHTS, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced today that Tonix management will present and host investor meetings at the following January 2026 investor conferences.

Sachs Associates 9^th Annual Neuroscience Innovation Forum
Company Presentation
Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Date: Sunday, January 11, 2026
Place: Marines’ Memorial Club & Hotel, San Francisco, Calif.
Time: 11:55 a.m. PT
Room: Track A, Rosenberg Room

Sachs Associates 9^th Annual Neuroscience Innovation Forum
Panel
Participant: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Title: Innovation in Neuropsychiatric Drug Development Panel
Date: Sunday, January 11, 2026
Place: Marines’ Memorial Club & Hotel, San Francisco, Calif.
Time: 1:15 p.m. PT

Biotech Showcase 2026
Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Date: Tuesday, January 13, 2026
Place: Hilton San Francisco Union Square, San Francisco, Calif.
Time: 11:00 a.m. PT
Room: Yosemite C
A replay of the presentation will be available on the Tonix website at www.tonixpharma.com following the presentation.

Investors interested in arranging a meeting with the Company’s management during these conferences should contact: sebastian.gomez@astrpartners.com

Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals is a fully-integrated biotechnology company with marketed products and a pipeline of development candidates. Tonix markets FDA-approved TONMYA^TM, a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. TONMYA is the first new prescription medicine approved by the FDA for fibromyalgia in more than 15 years. TONMYA was investigated as TNX-102 SL. Tonix also markets two treatments for acute migraine in adults: Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray). Tonix’s development portfolio* is focused on central nervous system (CNS) disorders, immunology, immuno-oncology, rare disease and infectious disease. TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under an Investigator-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). TNX-102 SL is also in development for major depressive disorder. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a Phase 2- ready Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s rare disease portfolio includes TNX-2900, intranasal oxytocin potentiated with magnesium, in development for Prader-Willi syndrome and expected to start a potential pivotal Phase 2 study in 2026. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4800, a Phase 2- ready long-acting humanized monoclonal antibody for the seasonal prevention of Lyme disease. Finally, TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years, is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of high lethality infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.

*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication under development.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize Tonmya and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris 
Tonix Pharmaceuticals 
investor.relations@tonixpharma.com 
(862) 799-8599 

Brian Korb 
astr partners 
(917) 653-5122 
brian.korb@astrpartners.com 

Media Contacts
Mary Ann Ondish
MaryAnn.Ondish@tonixpharma.com
(862) 799-8599

Ray Jordan 
Putnam Insights 
ray@putnaminsights.com 
 

INDICATION
TONMYA is indicated for the treatment of fibromyalgia in adults.

CONTRAINDICATIONS
TONMYA is contraindicated:
In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected.

With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.

During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.

In patients with hyperthyroidism.

WARNINGS AND PRECAUTIONS
Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.

Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases.

Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures.

Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.

CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities.

Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur.

ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.

DRUG INTERACTIONS

MAO inhibitors: Life-threatening interactions may occur.

Other serotonergic drugs: Serotonin syndrome has been reported.

CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced.

Tramadol: Seizure risk may be enhanced.

Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked.

USE IN SPECIFIC POPULATIONS
Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED).

Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of TONMYA have not been established.

Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions.

Please see additional safety information in the full Prescribing Information.
To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

FAQ

When will Tonix (TNXP) present at the Sachs Neuroscience Innovation Forum in January 2026?

Tonix will present on January 11, 2026 at 11:55 a.m. PT, with a panel participation at 1:15 p.m. PT.

When and where will Tonix (TNXP) present at Biotech Showcase 2026?

Tonix will present at Biotech Showcase on January 13, 2026 at 11:00 a.m. PT at the Hilton San Francisco Union Square; the replay will be on the company website.

How can investors schedule meetings with Tonix management at the January 2026 conferences?

Investors can request meetings by contacting sebastian.gomez@astrpartners.com.

What marketed products does Tonix (TNXP) cite in the January 2026 announcement?

Tonix markets TONMYA for fibromyalgia and two acute migraine treatments: Zembrace SymTouch and Tosymra.

Which Tonix development programs were highlighted ahead of the January 2026 presentations?

Highlighted programs include TNX-102 SL, TNX-1500, TNX-2900, TNX-801, TNX-4800, and TNX-4200 with a DTRA contract up to $34M.